Consulting firm McKinsey to pay $650 million to end opioid criminal probe
The investigation stems from the company’s work advising Purdue Pharma on how to “turbocharge” sales of the blockbuster opioid OxyContin, officials said.
View original article
Contributor: David Ovalle
